Design, synthesis, and cytotoxic activities of new 2,4,5-triarylimidazoles

Medicinal Chemistry Research

Volumn 22, Issue 8, 2013, Pages 3897-3904

  Zarghi, A ^a   Arfaei, S ^a   Shirazi, F H ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

2,4,5 Triarylimidazoles; Cytotoxic activity; Docking study; MTT; Synthesis

Indexed keywords

1 [2 [4 [2 (4 FLUOROPHENYL) 4 PHENYL 1H IMIDAZOL 5 YL]PHENOXY]ETHYL]PIPERIDINE; 1 [2 [4 [2 (4 METHOXYPHENYL) 4 PHENYL 1H IMIDAZOL 5 YL]PHENOXY]ETHYL]PIPERIDINE; 2 [4 (2,4 DIPHENYL 1H IMIDAZOL 5 YL)PHENOXY] N,N DIMETHYLETHANAMINE; 2 [4 [2 (4 FLUOROPHENYL) 4 PHENYL 1H IMIDAZOL 5 YL]PHENOXY] N,N DIMETHYLETHANAMINE; 2 [4 [2 (4 METHOXYPHENYL) 4 PHENYL 1H IMIDAZOL 5 YL]PHENOXY] N,N DIMETHYLETHANAMINE; 2,4,5 TRIARYLIMIDAZOLE DERIVATIVE; 4 [5 [4 (2 PIPERIDIN 1 YL)ETHOXY]PHENYL] 4 PHENYL 1H IMIDAZOL 2 YL]PHENOL; 4 [5 [4 (DIMETHYLAMINO)ETHOXY]PHENYL] 4 PHENYL 1H IMIDAZOL 2 YL]PHENOL; CYTOTOXIC AGENT; IMIDAZOLE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CYTOTOXICITY; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; MOLECULAR DOCKING;

EID: 84879507428     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0391-5     Document Type: Article

References (23)

1. Ali HI, Ashida N, Nagamatsu T (2007) Antitumor studies. Part 3: design, synthesis, antitumor activity and molecular docking study of novel 2-methylthio-, 2-amino-, and 2-(N-substituted amino)-10-alkyl-2-deoxo-5- deazaflavins. Bioorg Med Chem 15:6336-6352
2. Barrett I, Meegan MJ, Hughes RB, Carr M, Knox AJS, Artemenko N, Golfis G, Zisterer DM, Lloyd DG (2008) Synthesis, biological evaluation, structural-activity relationship and docking study for a series of benzoxepin derived estrogen receptor modulators. Bioorg Med Chem 16:9554-9573
3. Brogden RN, Heel RC, Speight TM, Avery GS (1978) Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use. Drugs 16:387-417
4. Caturla F, Jimenez JM, Godessart N, Amat M, Cardenas A, Soca L, Beleta J, Ryder H, Crespo Ml (2004) Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors. J Med Chem 47:3874-3886
5. Dhingra K (1999) Antiestrogens: tamoxifen, SERMs and beyond. Invest New Drugs 17:285-311
6. Di Santo R, Tafi A, Costi R, Botta M, Artico M, Corelli F, Forte M, Caporuscio F, Angiolella L, Palamara AT (2005) Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1H-pyrrol-3-yl)methyl]-1H- imidazole: synthesis, anti-candida activity, and QSAR studies. J Med Chem 48:5140-5153
7. Dickstein B, Valverius EM, Wosikowski K, Saceda M, Pearson JW, Martn MB, Mates SE (1993) Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. J Cell Physiol 157:110-118
8. Ellis PA, Saccani-Jotti G, Clarke R, Johnston SRD, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R, Robertson J, Smith IE, Dowsett (1997) Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 72:608-613
9. Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaicik S, Brener HJ (1979) Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 15:659-670
10. Mano T, Stevens RW, Ando K, Nakao K, Okumura Y, Sakakibara M, Okumura T, Tamura T, Miyamoto K (2003) Novel imidazole compounds as a new series of potent, orally active inhibitors of 5-lipoxygenase. Bioorg Med Chem 11:3879-3887
11. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
12. Narasimhan B, Sharma D, Kumar P (2011) Biological importance of imidazole nucleus in the new millennium. Med Chem Res 20:1119-1140
13. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD (2000) Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 60:2964-2972
14. Osborne CK (1998) Drug therapy: tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618
15. Robert J, Jarry C (2003) Multidrug resistance reversal agents. J Med Chem 46:4805-4817
16. Siciliano MJ, Barker PE, Cailleau R (1979) Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res 39:919-922
17. Takle AK, Brown MJB, Davies S, Dean DK, Francis G, Gaiba A, Hird AW, King FD, Lovell PJ, Naylor A, Reith AD, Steadman JG, Wilson DM (2006) The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett 16:378-381
18. Trott O, Olson AJ (2010) AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multi threading. J Comput Chem 31:455-461
19. Um SJ, Park SH, Park CH, Chang BH, Yoon JH, Sin HS (2003) Synthesis of novel quinoline carboxamide derivatives with estrogenic activity. Bull Korean Chem Soc 24:677-680
20. Wahala K, Hase TA (1991) Expedient synthesis of polyhydroxyflavonoids. J Chem Soc Perkin Trans 1 1:3005-3008
21. Wang L, Woods KW, Li Q, Barr KJ, McCroskey RW, Hannick SM, Gherke L, Credo RB, Hui YH, Marsh K, Warner R, Lee JY, Zielinsky-Mozng N, Frost D, Rosenberg SH, Sham HL (2002) Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure - activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem 45:1697-1711
22. Wolkenberg SE, Wisnoski DD, Leister WH, Wang Y, Zhao Z, Lindsley CW (2004) Efficient synthesis of imidazoles from aldehydes and 1, 2-diketones using microwave irradiation. Org Lett 6:1453-1456
23. Zarghi A, Arfaei S, Ghodsi R (2012) Design and synthesis of new 2,4,5-triarylimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors. Med Chem Res 21:1803-1810